-transparent.png){kind=logo}
The binding sites for Ca2+ channel antagonists were probed using Bay P 8857 [2-iodoethyl isopropyl 1,4-dihydropyridine-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarbox ylate] that has been radiolabelled with 125I. This drug was shown to bind with high affinity to cardiac, smooth, and skeletal muscle membranes, with a KD approximately equal to 0.3 nM. A protein of molecular weight 33-35,000 daltons was specifically and irreversibly radiolabelled after irradiation of cardiac, skeletal and aortic smooth muscle membranes, incubated with the [125I]-Bay P 8857. The peptide labelled by 1,4-dihydropyridine binding therefore appears similar in size for cardiac, skeletal, and smooth muscle. This data suggests that of the three peptide subunits which reportedly comprise the skeletal and cardiac muscle 1,4-dihydropyridine receptor complex, the 33-35,000 dalton peptide contains the dihydropyridine binding site.
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
December 1986,
European journal of biochemistry,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
April 1987,
The Biochemical journal,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
November 1991,
DICP : the annals of pharmacotherapy,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
October 1995,
The Journal of biological chemistry,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
February 1987,
FEBS letters,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
December 1982,
Canadian journal of physiology and pharmacology,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
January 2002,
Arzneimittel-Forschung,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
December 1989,
Biochemical pharmacology,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
July 1988,
The Biochemical journal,
J G Sarmiento, and
P M Epstein, and
W A Rowe, and
D W Chester, and
H Smilowitz, and
E Wehinger, and
R A Janis
January 1985,
Biochemical and biophysical research communications,
